Background: Glycolipid Metabolic Disorders (GLMD) are characterized by imbalances in glucose and lipid homeostasis, often presenting with severe clinical symptoms. Current pharmacotherapies such as orlistat and metformin show clear efficacy but are associated with long-term tolerability concerns. This study aimed to evaluate whether the next-generation probiotic candidate Methods: A high-fat diet (HFD)-induced mouse model of glycolipid metabolic disturbance was used, with YGMCC0564 supplementation initiated concurrently with HFD feeding in a prevention design. Results: YGMCC0564 attenuated HFD-induced body weight gain, dyslipidemia, and hyperglycemia, reduced hepatic steatosis and gluconeogenic gene expression, and improved insulin resistance. Multi-omics analysis showed that YGMCC0564 reshaped the gut microbiota and restored fecal short-chain fatty acid concentrations that had been reduced by HFD feeding. The fecal bile acid profile was remodeled, with elevated lithocholic acid (LCA) and 3β,7α-dihydroxy-5-cholestenoate and reduced α-muricholic acid (α-MCA), chenodeoxycholic acid (CDCA), taurodeoxycholic acid (TDCA), and isoLCA. Intestinal expression of Fxr, Fgf15, Gpbar1/Tgr5, and Glp-1 was upregulated, consistent with enhanced bile acid receptor signaling. Conclusion: These findings indicate that YGMCC0564 may modulate FXR-FGF15/19 and GPBAR1/TGR5 signaling via the gut environment, thereby potentially contributing to its hypoglycemic and hypolipidemic effects.